Compounds with anti-tumor activity against cancer cells bearing her2 exon 21 insertions
AssigneeBoard of Regents, The University of Texas System
InventorsJacqulyne ROBICHAUX, John V. HEYMACH
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods of treating cancer in a patient determined to have an HER2 exon 21 mutation by administering a third-generation tyrosine kinase inhibitor, such as poziotinib.
Claims59
A method of treating cancer in a subject comprising administering an effective amount of poziotinib to the subject, wherein the subject has been determined to have one or more HER2 exon 21 mutations.
The method of claim 15, wherein the genomic sample is isolated from saliva, blood, urine, normal tissue, or tumor tissue.
A pharmaceutical composition comprising poziotinib for use in a subject determined to have one or more HER exon 21 mutations.
A method of predicting a response to poziotinib alone or in combination with a second anti-cancer therapy in a subject having a cancer comprising detecting a HER2 exon 21 mutation in a genomic sample obtained from said patient, wherein if the sample is positive for the presence of the HER2 exon 21 mutation, then the patient is predicted to have a favorable response to the poziotinib alone or in combination with an anti-cancer therapy.
Dependencies are inferred from the claim text.